SARS-CoV-2 vaccine uptake, perspectives, and adverse reactions following vaccination in patients with cancer undergoing treatment.

Competing Interests: Disclosure JG holds a consultant or advisory role at EMD Serono; Elsevier; Exelixis; QED Therapeutics; Natera, Basilea, HalioDx, Eisai, Janssen. KLR holds a consultant or advisory role at Amgen, AstraZeneca, Blueprint, Boehringer Ingelheim, Daiichi Sankyo, EMD Serono, Genentech, GSK, Janssen, Lilly, Merck KGA, Mirati, Seattle Genetics, Takeda. JD holds a consultant or advisory role at Kite Pharma and MorphoSys. RB holds a consultant or advisory role at Genomic Health, Astra Zeneca, Biotheranostics, Pfizer; she is on the Speakers Bureau for Genentech, Seattle Genetics; she also has research funding from Seattle Genetics, Ichnos Biosciences, Merck. All other authors have declared no conflicts of interest.